Prestige Consumer Healthcare (NYSE:PBH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Prestige Consumer Healthcare (NYSE:PBH - Free Report) from a hold rating to a buy rating in a report published on Saturday.

Separately, Royal Bank Of Canada raised shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Stock Down 0.2%

PBH traded down $0.17 during midday trading on Friday, reaching $78.75. 401,769 shares of the company were exchanged, compared to its average volume of 307,250. The company has a market cap of $3.89 billion, a price-to-earnings ratio of 18.36, a price-to-earnings-growth ratio of 2.37 and a beta of 0.43. Prestige Consumer Healthcare has a one year low of $64.94 and a one year high of $90.04. The company's fifty day moving average price is $84.13 and its 200 day moving average price is $82.43. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.82 and a current ratio of 4.20.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.02. The company had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. Prestige Consumer Healthcare's quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.02 earnings per share. As a group, analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several large investors have recently made changes to their positions in PBH. Charles Schwab Investment Management Inc. grew its position in Prestige Consumer Healthcare by 5.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 636,020 shares of the company's stock valued at $49,667,000 after buying an additional 33,844 shares during the period. Atria Investments Inc boosted its stake in Prestige Consumer Healthcare by 25.8% in the fourth quarter. Atria Investments Inc now owns 22,253 shares of the company's stock valued at $1,738,000 after acquiring an additional 4,570 shares during the last quarter. M&T Bank Corp grew its position in shares of Prestige Consumer Healthcare by 12.4% during the 4th quarter. M&T Bank Corp now owns 5,164 shares of the company's stock valued at $404,000 after acquiring an additional 570 shares during the period. Proficio Capital Partners LLC bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at approximately $1,689,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $42,593,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.